NasdaqCM - Delayed Quote USD

NEXGEL, Inc. (NXGLW)

0.3010
-0.0590
(-16.39%)
At close: May 22 at 4:00:00 PM EDT
Loading Chart for NXGLW
  • Previous Close 0.3600
  • Open 0.2900
  • Bid --
  • Ask --
  • Day's Range 0.2805 - 0.3010
  • 52 Week Range 0.2805 - 0.3010
  • Volume 720
  • Avg. Volume --
  • Market Cap (intraday) --
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -1.3900
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

NEXGEL, Inc. manufactures and sells high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also developing NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment. In addition, the company engages in the converting and packaging business. It serves its customers under Medagel, Lumagel Beauty, Kenkoderm and Silly George brand names. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was incorporated in 2009 and is based in Langhorne, Pennsylvania.

nexgel.com

19

Full Time Employees

--

Fiscal Year Ends

Recent News: NXGLW

View More

Compare To: NXGLW

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NXGLW

View More

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -30.70%

  • Return on Assets (ttm)

    -20.77%

  • Return on Equity (ttm)

    -60.08%

  • Revenue (ttm)

    10.23M

  • Net Income Avi to Common (ttm)

    -3.14M

  • Diluted EPS (ttm)

    -1.3900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.19M

  • Total Debt/Equity (mrq)

    49.25%

  • Levered Free Cash Flow (ttm)

    -2.7M

Research Analysis: NXGLW

View More

Company Insights: NXGLW

Research Reports: NXGLW

View More

People Also Watch